| Name | Title | Contact Details |
|---|
WE ARE A DESIGN COMPANY. Allovus is a woman-owned equal opportunity employer committed to fostering an inclusive and creative environment. Our employees produce meaningful work, create strong community connections, and inspire delight in our clients. Studio Our skilled and collaborative Design Studio team provides beautiful, elegant, and functional solutions for our clients. No matter the creative challenge, our intentionally small and agile team operates as a one-stop design shop. Custom Solutions Deliverable based teams, managed for you. In todays world, many of our clients are looking for ways to augment their own teams with creative talent in different ways outside the typical individual contractor approach. Our ability to build, nurture, and employ teams of people is one of our strongest attributes as an organization. Were excited to provide a model to our clients which allows you to retain a world-class team, while meeting the compliance standards of your organization, all while delivering amazing designs on time and on budget. Search We specialize in permanent placement using a holistic, qualitative approach to make the perfect match.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
BlueScope Buildings North America, Inc. is a leading manufacturer of engineered building solutions. We custom-engineer and manufacture low-rise building envelopes using automated design technology to create an integrated building system. We are uniquely positioned to support facility expansion plans for corporations in logistics, beverage, manufacturing, mining, transportation, retail and other industries. BlueScope Buildings North America is the North American footprint of BlueScope Buildings. BlueScope Buildings is a business unit of public-traded BlueScope Ltd. (ASX: BSL)
We are a trusted partner and advisor to executives, founders and funders – bringing strategic and tactical knowledge, expertise and tools that help them solve problems, overcome challenges and reclaim time. We provide a tailored suite of cross-functional services designed to empower and enable brands to grow, drive revenue, operate with ease and transform company culture.